Tailored assembly synthesis of newly functionalized ruthenium (II)-urea-linked-warfarin complex-leads to coordinated MOFs as anticancer

Abstract

It is well known that, warfarin is fundamentally used as anticoagulant, but in these studies a new strategies are applied to replace the main warfarin-pharmacophore thoroughly addition of urea to condense with keto (C = O) group of basic 4-hydroxy coumarin to be an active new site (-C = N-CO = N-). The initially formed Ru(II)-modified warfarin complex which is considered the monomeric unit complex of the finally produced Ru(II)-MOFs was carefully characterized by Raman spectra, TGA-thermo-gravimetric analysis,1H NMR,as well as micro-elemental analysis and UV/Vis spectroscopy to prove structure. The chemically modified Ru(II)-urea-linked warfarin MOFs exhibited ultrahigh BET surface area of ~ 924 m2g−1. Ru(II)-MOFs were successfully synthesized via microwave-hydrothermal procedures. The final product of ruthenium (II)-MOFs exhibited moderate to strong anticancer activity towards some common tested cancer cells.